[go: up one dir, main page]

AR096748A1 - Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina - Google Patents

Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina

Info

Publication number
AR096748A1
AR096748A1 ARP140102420A ARP140102420A AR096748A1 AR 096748 A1 AR096748 A1 AR 096748A1 AR P140102420 A ARP140102420 A AR P140102420A AR P140102420 A ARP140102420 A AR P140102420A AR 096748 A1 AR096748 A1 AR 096748A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
group
haloalkyl
independently selected
Prior art date
Application number
ARP140102420A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51205521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR096748(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR096748A1 publication Critical patent/AR096748A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos útiles para utilizar como medicamentos para controlar trastornos psiquiátricos y neurológicos, y sales farmacéuticamente aceptables de los mismos; procesos como la preparación de intermediarios utilizados en la preparación de; y composiciones que contienen los compuestos o sales, y su usos para tratar los trastornos mediados por D1 (o asociados con D1) que incluyen, por ejemplo, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), discapacidad cognitiva (por ejemplo, discapacidad cognitiva asociada con esquizofrenia, AD, PD, o terapia de farmacoterapia), declive cognitivo relacionado con la edad, demencia y enfermedad de Parkinson. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: cada uno de T¹, T², T³, y T⁴ se selecciona independientemente del grupo que consiste de H, halógeno, -CN, -SF₅, -OH, -N(Rᵃ)(Rᵇ), -C(=O)-N(Rᵃ)(Rᵇ), -C(=O)-ORᶜ, -C(=O)-Rᵈ, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, -S-(alquilo C₁₋₆), cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 7 miembros, cicloalcoxi C₃₋₇ heteroarilo de 5 ó 6 miembros, ciclopropilmetilo, y ciclobutilmetilo, en donde cada uno del alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, -S-(alquilo C₁₋₆), y alcoxi C₁₋₆ se sustituye opcionalmente con uno o más sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -OH, -CN, -N(Rᵃ)(Rᵇ), alcoxi C₁₋₄, haloalcoxi C₁₋₄, y -S-(alquilo C₁₋₄); y en donde cada uno del cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 7 miembros, cicloalcoxi C₃₋₇, heteroarilo de 5 ó 6 miembros, ciclopropilmetilo, y ciclobutilmetilo de T¹, T², y T³ se sustituye opcionalmente con uno o más sustituyentes cada uno es seleccionado independientemente del grupo que consiste de halógeno, -OH, -CN, oxo, -N(Rᵃ)(Rᵇ), -C(=O)OH, -C(=O)-alquilo C₁₋₄, -C(=O)-O-alquilo C₁₋₄, -C(=O)-N(Rᵃ)(Rᵇ), alquilo C₁₋₄, haloalquilo C₁₋₄, hidroxilalquilo C₁₋₄, cianoalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄, y -S-(alquilo C₁₋₄); L¹ se selecciona del grupo que consiste de O, S, NH, N(alquilo C₁₋₄), N(-alquilo C₁₋₂-cicloalquilo C₃₋₄), y N(cicloalquilo C₃₋₆); cada uno de Rᵃ y Rᵇ se selección independientemente del grupo que consiste de H, alquilo C₁₋₄, cicloalquilo C₃₋₇, y ciclopropilmetilo; o Rᵃ y Rᵇ junto con el átomo N al cual se unen forman heterocicloalquilo de 4 a 7 miembros opcionalmente sustituido con uno o más sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -OH, -CN, oxo, -NH₂, -NH(alquilo C₁₋₄), -N(alquilo C₁₋₄)₂, -C(=O)OH, -C(=O)-alquilo C₁₋₄, -C(=O)-O-alquilo C₁₋₄, -C(=O)-NH₂, -C(=O)-NH(alquilo C₁₋₄), -C(=O)-N(alquilo C₁₋₄)₂, alquilo C₁₋₄, haloalquilo C₁₋₄, hidroxilalquilo C₁₋₄, cianoalquilo C₁₋₄, alcoxi C₁₋₄, -S-(alquilo C₁₋₄), y haloalcoxi C₁₋₄; cada uno de Rᶜ y Rᵈ es independientemente alquilo C₁₋₄, cicloalquilo C₃₋₄-alquilo C₁₋₂-, o cicloalquilo C₃₋₄; Q¹ se selecciona del grupo que consiste de Q¹ᵃ, Q¹ᵇ, Q¹ᶜ, Q¹ᵈ y Q¹ᵉ del grupo de fórmulas (2); condición de (a) que un átomo de carbono del anillo Q¹ se encuentre unido al anillo benceno de la fórmula (1) y (b) que cuando L¹ es NH, entonces el anillo Q¹ se sustituya con al menos uno que no sea H R⁹, R¹⁰, R¹¹, R¹², R¹³, R⁹A, R¹⁰A, R¹⁰B, R¹¹A, R¹²A ó R¹³A; cada uno de X¹ y X² es independientemente O ó S; cada uno de R¹, R², R³, y R⁴ se selecciona independientemente del grupo que consiste de H, halógeno, -OH, -NO₂, -CN, -SF₅, alquilo C₁₋₆, haloalquilo C₁₋₆ haloalcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 10 miembros, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -C(=O)-(R⁵)(R⁶), -C(=O)-R⁸, -C(=O)-OR⁸, -N(R⁷)(S(=O)₂R⁸), -S(=O)₂-N(R⁵)(R⁶), -SR⁸, y -OR⁸, en donde cada uno del alquilo C₁₋₆, cicloalquilo C₃₋₇, y heterocicloalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -CN, oxo, -OH, alquilo C₁₋₄, alcoxi C₁₋₄, haloalquilo C₁₋₄, haloalcoxi C₁₋₄, cicloalquilo C₃₋₆, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -C(=O)-OR⁸, -C(=O)H, -C(=O)R⁸, -C(=O)N(R⁵)(R⁶), -N(R⁷)(S(=O)₂R⁸), -S(=O)₂-N(R⁵)(R⁶), -SR⁸, y -OR⁸; o R² y R⁴ junto con los dos átomos al cual se unen forman un heteroarilo fusionado de 5 ó 6 miembros, un anillo heterocicloalquilo fusionado de 5 ó 6 miembros, un anillo cicloalquilo fusionado de 5 ó 6 miembros, o un anillo benceno fusionado, en donde cada uno de los anillos fusionados se sustituye opcionalmente con 1, 2, ó 3 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halo, -CN, -OH, alquilo C₁₋₄, alcoxi C₁₋₄, haloalquilo C₁₋₄, y haloalcoxi C₁₋₄, y en donde el anillo heterocicloalquilo fusionado o anillo cicloalquilo fusionado además se sustituye opcionalmente con 1, 2, ó 3 oxo; R⁵ es H, alquilo C₁₋₄, haloalquilo C₁₋₄, o cicloalquilo C₃₋₇; R⁶ es H o se selecciona del grupo que consiste de alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 10 miembros, arilo C₆₋₁₀, un heteroarilo de 5 a 10 miembros, (cicloalquilo C₃₋₇)-alquilo C₁₋₄-, (heterocicloalquilo de 4 a 10 miembros)-alquilo C₁₋₄-, (arilo C₆₋₁₀)-alquilo C₁₋₄-, y (heteroarilo de 5 a 10 miembros)-alquilo C₁₋₄-, en donde cada uno se selecciona del grupo que se sustituye opcionalmente con 1, 2, 3, ó 4 sustituyentes cada uno seleccionado independientemente del grupo que consiste de -OH, -CN, alquilo C₁₋₄, cicloalquilo C₃₋₇, hidroxilalquilo C₁₋₄, -S-alquilo C₁₋₄, -C(=O)H, -C(=O)-alquilo C₁₋₄, -C(=O)-O-alquilo C₁₋₄, -C(=O)-NH₂, -C(=O)-N(alquilo C₁₋₄)₂, haloalquilo C₁₋₄, alcoxi C₁₋₄, y haloalcoxi C₁₋₄; o R⁵ y R⁶ junto con el átomo N al cual se unen forman heterocicloalquilo de 4 a 10 miembros o un heteroarilo de 5 a 10 miembros, cada uno opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -OH, oxo, -C(=O)H, -C(=O)-alquilo C₁₋₄, -C(=O)OH, -C(=O)-O-alquilo C₁₋₄, -C(=O)-NH₂, -C(=O)-N(alquilo C₁₋₄)₂, -CN, alquilo C₁₋₄, alcoxi C₁₋₄, hidroxilalquilo C₁₋₄, haloalquilo C₁₋₄, y haloalcoxi C₁₋₄; R⁷ se selecciona del grupo que consiste de H, alquilo C₁₋₄, y cicloalquilo C₃₋₇; R⁸ se selecciona del grupo que consiste de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 10 miembros, arilo C₁₋₆, un heteroarilo de 5 a 10 miembros, (cicloalquilo C₃₋₄)-alquilo C₁₋₄-, (heterocicloalquilo de 4 a 10 miembros)-alquilo C₁₋₄-, (arilo C₆₋₁₀)-alquilo C₁₋₄-, y (heteroarilo de 5 a 10 miembros)-alquilo C₁₋₄-, en donde cada uno se selecciona del grupo que se sustituye opcionalmente con 1, 2, ó 3 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -CF₃, -CN, -OH, oxo, -S-alquilo C₁₋₄, alquilo C₁₋₄, haloalquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₇, alcoxi C₁₋₄, y haloalcoxi C₁₋₄; cada R⁹ y R¹² se selecciona independientemente del grupo que consiste de halógeno, -OH, -CN, -SF₅,
ARP140102420A 2013-06-27 2014-06-26 Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina AR096748A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361840144P 2013-06-27 2013-06-27

Publications (1)

Publication Number Publication Date
AR096748A1 true AR096748A1 (es) 2016-02-03

Family

ID=51205521

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102420A AR096748A1 (es) 2013-06-27 2014-06-26 Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina

Country Status (41)

Country Link
US (10) US9527831B2 (es)
EP (2) EP3421462B1 (es)
JP (1) JP6026024B2 (es)
KR (1) KR101781723B1 (es)
CN (1) CN105324376B (es)
AP (1) AP2015008844A0 (es)
AR (1) AR096748A1 (es)
AU (1) AU2014300673B2 (es)
BR (1) BR122023004130B1 (es)
CA (1) CA2916653C (es)
CL (1) CL2015003735A1 (es)
CR (1) CR20150634A (es)
CU (1) CU24334B1 (es)
DK (2) DK3421462T3 (es)
DO (1) DOP2015000302A (es)
EA (1) EA028637B1 (es)
EC (1) ECSP16003103A (es)
ES (2) ES2729630T3 (es)
FI (1) FI3421462T3 (es)
GT (1) GT201500350A (es)
HR (2) HRP20230546T1 (es)
HU (2) HUE062265T2 (es)
IL (1) IL242480B (es)
MA (1) MA38661A1 (es)
MD (1) MD20150122A2 (es)
MX (2) MX394241B (es)
NI (1) NI201500179A (es)
NZ (1) NZ713762A (es)
PE (1) PE20160664A1 (es)
PH (1) PH12015502502A1 (es)
PL (2) PL3013813T3 (es)
PT (2) PT3421462T (es)
RS (2) RS59018B1 (es)
SG (1) SG11201509186TA (es)
TN (1) TN2015000547A1 (es)
TR (1) TR201907981T4 (es)
TW (1) TWI508957B (es)
UA (1) UA112945C2 (es)
UY (1) UY35628A (es)
WO (1) WO2014207601A1 (es)
ZA (1) ZA201508252B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5857168B2 (ja) 2012-11-08 2016-02-10 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用
FI3421462T3 (fi) * 2013-06-27 2023-06-26 Pfizer Heteroaromaattisia yhdisteitä ja niiden käyttö dopamiini-d1-ligandeina
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
AU2015249496A1 (en) 2014-04-25 2016-09-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
AU2015249497A1 (en) 2014-04-25 2016-10-20 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3137469B1 (en) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclic compounds and their use as dopamine d1 ligands
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
WO2017066402A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
PL3389727T3 (pl) 2015-12-18 2021-02-08 Janssen Pharmaceutica Nv RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET
EP3389728B1 (en) 2015-12-18 2020-08-05 Janssen Pharmaceutica NV Radiolabelled mglur2/3 pet ligands
WO2017122116A1 (en) 2016-01-15 2017-07-20 Pfizer Inc. 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺
UA123706C2 (uk) 2016-03-30 2021-05-19 Ісіхара Сангіо Кайся, Лтд. Сполука піридазинону або її сіль і гербіцид, що містить зазначену сполуку
CN108530310B (zh) * 2017-03-02 2025-01-28 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2021216898A1 (en) * 2020-04-23 2021-10-28 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
TW202222163A (zh) * 2020-08-14 2022-06-16 瑞士商先正達農作物保護公司 化學方法
AU2022402852A1 (en) 2021-12-03 2024-06-20 Abbvie Inc. Solid state forms of tavapadon and processes for preparation thereof
CN118401513A (zh) * 2022-01-29 2024-07-26 苏州科睿思制药有限公司 他伐帕敦的晶型及其制备方法和用途
WO2025037213A1 (en) * 2023-08-11 2025-02-20 Mankind Pharma Ltd. Pharmaceutical formulations of gpr119 agonists and uses thereof
WO2025144911A1 (en) 2023-12-27 2025-07-03 Pfizer Inc. Solid forms of 6-[4-[[3-(difluoromethoxy)-2-pyridinyl]oxy]-2-methylphenyl]-1,5-dimethyl-2,4(1h, 3h)-pyrimidinedione, a

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5025142B1 (es) 1969-07-30 1975-08-21
JPS5039272B1 (es) 1970-07-14 1975-12-16
JPS5025142A (es) 1973-07-06 1975-03-17
JPS5039272A (es) 1973-08-10 1975-04-11
JPS5516432B2 (es) 1974-05-28 1980-05-01
JPS51113899A (en) 1975-03-27 1976-10-07 Yoshitomi Pharmaceut Ind Ltd Method for preparing novel tetrazole derivatives
JPS522031A (en) 1975-06-24 1977-01-08 Japan Niyuupureito Hokushiyou Sunshade device
EP0002812B1 (de) 1978-01-02 1982-02-03 Ciba-Geigy Ag Phenoxy-alkyl-oxazoline, ihre Herstellung, sie enthaltende Mittel sowie deren Verwendung als Herbizide
EP0101662A3 (de) 1982-06-25 1985-12-04 Ciba-Geigy Ag Benzoylparabansäuren
US4550108A (en) 1983-08-17 1985-10-29 Ciba Geigy Corporation 1,3,5-Oxadiazine-2,4-diones and pesticidal use
US4723015A (en) 1983-10-17 1988-02-02 Ciba-Geigy Corporation Certain insecticidal N-2-pyridyloxyphenylbenzimidates
IL73611A0 (en) 1983-12-06 1985-02-28 Nippon Soda Co 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides
JPS61275271A (ja) 1985-05-30 1986-12-05 Nippon Soda Co Ltd １，２，４−オキサ（チア）ジアゾリン誘導体、その製造方法，殺虫剤及び農園芸用殺菌剤
DE3545786A1 (de) 1985-12-21 1987-06-25 Schering Ag Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung
DE3545569A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3631511A1 (de) 1986-09-12 1988-03-24 Schering Ag 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel
EP0296518A1 (de) 1987-06-22 1988-12-28 Ciba-Geigy Ag Neue Phenylether-derivate als Mikrobizide, Verfahren zu deren Herstellung und deren Verwendung
DE3826855A1 (de) * 1988-08-06 1990-02-15 Cassella Ag 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
JPH0259574A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ピラジノン誘導体又はその塩類
JPH0259573A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ２（１ｈ）−ピリミジノン誘導体又はその塩類
US5066667A (en) 1989-06-26 1991-11-19 Ciba-Geigy Corporation Thioxotetrazolines and insecticidal use thereof
ATE111901T1 (de) 1990-01-18 1994-10-15 Nissan Chemical Ind Ltd Uracilderivate und pestizide, die diese als wirksame stoffe enthalten.
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH03261783A (ja) 1990-03-12 1991-11-21 Suntory Ltd １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
JP3018422B2 (ja) 1990-07-27 2000-03-13 日東紡績株式会社 床 材
US5630962A (en) 1990-12-19 1997-05-20 Hoechst Aktiengesellschaft 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH05202031A (ja) 1992-01-28 1993-08-10 Nissan Chem Ind Ltd Ｎ−アミノピリミジンジオン誘導体および除草剤
WO1993018016A1 (en) 1992-03-11 1993-09-16 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
US5482951A (en) 1992-05-29 1996-01-09 Kumiai Chemical Industry Co., Ltd. Triazole derivatives as well as insecticide and acaricide
AU4950793A (en) 1992-08-31 1994-03-29 Ciba-Geigy Ag 4,5-dicyanoimidazole derivatives and pesticidal compositions containing them
NZ259033A (en) 1992-12-25 1997-01-29 Nippon Soda Co 1,3-(thio)morpholine derivatives and biocidal compositions thereof
JP3682075B2 (ja) 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
EP0712847A4 (en) 1993-08-11 1997-05-28 Nippon Soda Co IMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A PEST CONTROL
JPH0873446A (ja) 1994-04-22 1996-03-19 Nippon Soda Co Ltd ヘテロ環化合物および殺虫・殺ダニ剤
JPH0827120A (ja) 1994-07-08 1996-01-30 Nissan Chem Ind Ltd テトラヒドロピリミジノン誘導体
JPH08217777A (ja) 1995-02-10 1996-08-27 Nippon Nohyaku Co Ltd ２−ピラゾリン−５−オン誘導体及びその中間体並びに除草剤
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH09291282A (ja) 1996-04-26 1997-11-11 Sumitomo Chem Co Ltd 安定化した液晶材料およびこれを用いた液晶素子
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1030843A4 (en) * 1997-10-27 2002-11-06 Isk Americas Inc SUBSTITUTED BENZENE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND HERBICIDES AND LEAVING COMPOSITIONS THAT CONTAIN THEM
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
JP4610738B2 (ja) 1998-10-23 2011-01-12 ダウ・アグロサイエンス・エル・エル・シー 殺虫性１−（置換ピリジル）−１，２，４−トリアゾール
GB9903671D0 (en) * 1999-02-17 1999-04-14 Cenes Ltd Dopamine D-1 receptor agonist compounds
MXPA02007047A (es) 2000-01-18 2002-12-13 Pfizer Prod Inc Antagonista del factor liberador de corticotropina.
WO2001074331A1 (en) 2000-04-04 2001-10-11 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
US6476055B1 (en) 2001-03-28 2002-11-05 Nippon Soda Co. Ltd. 5,5-disubstituted thiazolidine derivative pesticides
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
CN1522251A (zh) 2001-05-09 2004-08-18 ס������ũҩ��ʽ���� 唑化合物及其制备方法和应用
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2004018410A1 (ja) 2002-08-26 2004-03-04 Nissan Chemical Industries, Ltd. 置換ベンズアニリド化合物及び有害生物防除剤
EP1575919A1 (en) 2002-11-11 2005-09-21 Bayer HealthCare AG Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US6969744B2 (en) 2003-06-19 2005-11-29 University Of Southern Mississippi Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation
AP2006003534A0 (en) 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
JP4451849B2 (ja) 2003-11-28 2010-04-14 日本曹達株式会社 アリール複素環誘導体および農園芸用殺菌剤および殺虫剤
JP2005272452A (ja) 2004-02-23 2005-10-06 Nissan Chem Ind Ltd 置換ベンズアニリド化合物及び有害生物防除剤
WO2005102389A2 (en) 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
US7880000B2 (en) 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
TW200612827A (en) 2004-08-25 2006-05-01 Sumitomo Chemical Co Insecticide composition
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
JP2009535307A (ja) 2006-04-28 2009-10-01 アベキサ・リミテッド インテグラーゼ阻害剤３
TW200820970A (en) 2006-09-21 2008-05-16 Nicholas Piramal India Ltd Compounds for the treatment of metabolic disorders
EP2256496A3 (en) 2006-09-21 2011-03-16 Piramal Life Sciences Limited Method for identifying compounds that act as insulin-sensitizers
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
EP1916240A1 (en) 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
DE102007003036A1 (de) 2006-12-20 2008-06-26 Bayer Cropscience Ag Pyrimidinylpyrazole
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
RU2532135C2 (ru) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Производные иминопиридина и их применение в качестве микробиоцидов
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101294257B (zh) 2007-04-23 2014-06-18 株式会社神户制钢所 焊接热影响部的韧性优异的钢材及其制造方法
JP2009062290A (ja) 2007-09-04 2009-03-26 Takeda Chem Ind Ltd シクロプロパン化合物
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
RU2485103C2 (ru) * 2007-10-31 2013-06-20 Эбботт Гмбх Унд Ко.Кг Бензолсульфаномидные соединения, пригодные для лечения расстройств, которые восприимчивы к модуляции дофаминового рецептора d3
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
MX2011000175A (es) 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
WO2010029299A1 (en) * 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivaties for use as medicaments
JP5636286B2 (ja) 2008-12-03 2014-12-03 日本農薬株式会社 ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
EP2246335A1 (de) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
HUE036431T2 (hu) 2010-03-04 2018-07-30 Merck Sharp & Dohme Katechin o-metil transzferáz gátlók és alkalmazásuk pszichotikus betegségek kezelésében
BR112012026641A2 (pt) 2010-04-23 2016-07-12 Kineta Inc compostos antivirais
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
LT2603513T (lt) 2010-08-10 2020-05-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
JP5941546B2 (ja) * 2011-09-02 2016-06-29 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリミジン
AP3861A (en) * 2012-11-08 2016-10-31 Pfizer Heteroaromatic compounds as dopamine d1 ligands
JP5857168B2 (ja) * 2012-11-08 2016-02-10 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用
WO2014119770A1 (ja) * 2013-01-30 2014-08-07 住友化学株式会社 ピリダジノン化合物及びそれを含有する除草剤
FI3421462T3 (fi) 2013-06-27 2023-06-26 Pfizer Heteroaromaattisia yhdisteitä ja niiden käyttö dopamiini-d1-ligandeina

Also Published As

Publication number Publication date
MD20150122A2 (ro) 2016-05-31
US20150005313A1 (en) 2015-01-01
US11014909B2 (en) 2021-05-25
UY35628A (es) 2015-01-30
AU2014300673A1 (en) 2015-11-12
KR101781723B1 (ko) 2017-10-23
EP3421462B1 (en) 2023-04-05
EP3013813A1 (en) 2016-05-04
US11964961B2 (en) 2024-04-23
CA2916653A1 (en) 2014-12-31
MX2015017169A (es) 2016-04-06
HRP20191163T1 (hr) 2019-10-04
DK3013813T3 (da) 2019-06-03
TW201512185A (zh) 2015-04-01
BR122023004130B1 (pt) 2023-12-12
UA112945C2 (uk) 2016-11-10
MX382599B (es) 2025-03-13
MX394241B (es) 2025-03-21
US20190002439A1 (en) 2019-01-03
US20240317713A1 (en) 2024-09-26
US20180037571A1 (en) 2018-02-08
DK3421462T3 (da) 2023-06-12
US20210300899A1 (en) 2021-09-30
PE20160664A1 (es) 2016-07-09
BR112015030101A2 (pt) 2017-07-25
TN2015000547A1 (fr) 2017-04-06
PL3421462T3 (pl) 2023-09-11
ES2948192T3 (es) 2023-09-01
TWI508957B (zh) 2015-11-21
US20190367485A1 (en) 2019-12-05
US20200283407A1 (en) 2020-09-10
US10696658B2 (en) 2020-06-30
CA2916653C (en) 2017-07-18
US10421744B2 (en) 2019-09-24
GT201500350A (es) 2017-09-28
US10093655B2 (en) 2018-10-09
EA028637B1 (ru) 2017-12-29
ZA201508252B (en) 2019-04-24
HUE062265T2 (hu) 2023-10-28
MA38661A1 (fr) 2017-03-31
US9822097B2 (en) 2017-11-21
PH12015502502A1 (en) 2016-02-22
CL2015003735A1 (es) 2016-06-24
CR20150634A (es) 2016-01-04
NI201500179A (es) 2016-02-11
SG11201509186TA (en) 2016-01-28
AP2015008844A0 (en) 2015-11-30
PT3013813T (pt) 2019-06-14
CN105324376B (zh) 2017-06-23
CU24334B1 (es) 2018-04-03
FI3421462T3 (fi) 2023-06-26
JP6026024B2 (ja) 2016-11-16
IL242480B (en) 2019-09-26
US9139561B2 (en) 2015-09-22
DOP2015000302A (es) 2016-02-29
US20170057947A1 (en) 2017-03-02
AU2014300673B2 (en) 2017-12-14
US20150175573A1 (en) 2015-06-25
RS59018B1 (sr) 2019-08-30
PL3013813T3 (pl) 2019-10-31
US9107923B2 (en) 2015-08-18
MX2020013099A (es) 2022-07-26
US20150196561A1 (en) 2015-07-16
IL242480A0 (en) 2016-02-01
PT3421462T (pt) 2023-06-29
HRP20230546T1 (hr) 2023-08-04
HUE043705T2 (hu) 2019-09-30
US9527831B2 (en) 2016-12-27
WO2014207601A1 (en) 2014-12-31
ECSP16003103A (es) 2017-08-31
KR20160014665A (ko) 2016-02-11
NZ713762A (en) 2018-03-23
RS64342B1 (sr) 2023-08-31
TR201907981T4 (tr) 2019-06-21
HK1215435A1 (zh) 2016-08-26
EP3421462A1 (en) 2019-01-02
EP3013813B1 (en) 2019-04-03
EA201592146A1 (ru) 2016-05-31
ES2729630T3 (es) 2019-11-05
CN105324376A (zh) 2016-02-10
CU20150180A7 (es) 2016-05-30
JP2016531083A (ja) 2016-10-06

Similar Documents

Publication Publication Date Title
AR096748A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
AR088327A1 (es) Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR103561A1 (es) Fenilpiridinas herbicidas
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR103252A1 (es) Compuestos de quinazolina
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
AR098912A1 (es) Inhibidores de syk
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR096709A1 (es) Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)
AR098522A1 (es) Compuesto de triazolo-piridina
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
AR105991A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR099047A1 (es) Derivados etinilo
AR095570A1 (es) Derivados de urea

Legal Events

Date Code Title Description
FB Suspension of granting procedure